Intermountain Health logo

Please enter the city or town where you'd like to find care.

Get care nowSign in

Health news and blog

    Dr. Pravin J. Mishra on ICG100

    Dr. Pravin J. Mishra on ICG100

    20150410 genomics lab05

    It is thrilling to be here at the American Society of Clinical Oncology Annual Meeting. I have dedicated my life to researching and developing strategies to conquer cancer. My colleagues, Lincoln Nadauld, MD, PhD, and Derrick Haslem, MD, and I are excited to introduce our groundbreaking technology - ICG100 - that will be published in an abstract at this conference.

    ICG100

     ICG100 is a comprehensive test that uses state-of-the-art next generation sequencing to find and target individual somatic mutations within cancer tumors. ICG100 is cost-effective and offers high sensitivity and reportage as well as superior capability for clinical management through the identification of actionable genes, genomics-driven personalized treatment plans, and precision cancer care.

    Identification of Actionable Genes

    DNA is extracted from a patient’s tumor specimen and is sequenced for 96 cancer-related genes which are commonly altered, or mutated. This panel targets regions using an in-solution oligo-capture sequencing method. Our test offers high coverage (>100X) and detects all classes of genomic alterations, including translocations, indels - insertions/deletions, copy number alterations (CNA’s) and point mutations. Our approach is viable and well suited for FFPE and fresh tissue samples.

    Genomic Personalized Treatment Plans

    In order to accommodate the diverse variants generated by our sequencing chemistry, we have developed a comprehensive, integrated service known as the molecular tumor board. This collaborative, interdisciplinary, board consists of expert scientists and physicians in genomics from across the western United States. The board meets weekly to discuss individual, effective treatment options based on genomic data and clinical relevance. Personalized, interpretive treatment plans are then linked with verified, precision cancer medications.

    Precision Cancer Care

    ICG100 can be ordered by any oncologist in the world through a simple web-based interface where genomic results and molecular tumor board recommendations are viewed. Additionally, oncologists can make a treatment selection and order precision medications with ease and convenience. End to end, the entire ICG100 process averages a 17 day turn-around time.

    For more information: visit Booth #16153 in the Oncology Professionals Hall or precisioncancer.org or follow Precision Genomics on Facebook.